Insta
Pfizer Seeking An “Expedited Approval Pathway” From India For The Roll-Out Of Its Two-Dose mRNA COVID-19 Vaccine
Pfizer logo (Pic Via Wikipedia)
United States (US) based biotechnology and pharmaceutical major Pfizer has said that the company is seeking an "expedited approval pathway" from New Delhi for the roll-out of its two-dose mRNA COVID-19 vaccine in India, reports Times of India.
The company's chief executive Albert Bourla took to social media and stated that its vaccine is not registered in India to date even though it had applied to the Government here months ago.
Meanwhile, the company also said that it is lining up $70 million worth of drug supplies to India to enhance the nation's capacity to cope with the surge in COVID-19 cases. The drug supplies include steroids, anticoagulants, and antibiotics.
Bourla added, "We are committed to being a partner in India's fight against the disease and are quickly working to mobilise the largest humanitarian relief effort in our company's history."
The statement, however, did not address the patent issue that many world leaders and activists, including WHO Director-General Tedros Adhanom Ghebreyesus and US Senator Bernie Sanders, say is at the heart of a long-term solution.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
